Core Laboratories is an oil & gas equipment & services business based in the US. Core Laboratories shares (CLB) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $20.31 – an increase of 1.8% over the previous week. Core Laboratories employs 3,500 staff and has a trailing 12-month revenue of around $522.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $20.31 |
|---|---|
| 52-week range | $13.80 - $25.11 |
| 50-day moving average | $18.88 |
| 200-day moving average | $18.28 |
| Wall St. target price | $20.43 |
| PE ratio | 36.9444 |
| Dividend yield | $0.04 (0.2%) |
| Earnings per share (TTM) | $0.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.8 from 2024-11-19
| 1 week (2024-11-14) | -0.75% |
|---|---|
| 1 month (2024-10-21) | 6.28% |
| 3 months (2024-08-21) | 7.78% |
| 6 months (2024-05-21) | 5.15% |
| 1 year (2023-11-21) | 8.55% |
|---|---|
| 2 years (2022-11-21) | -3.12% |
| 3 years (2021-11-19) | 24.2356 |
| 5 years (2019-11-21) | 45.0811 |
Valuing Core Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Core Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Core Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Core Laboratories shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Core Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8011. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Core Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Core Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $71.4 million.
The EBITDA is a measure of a Core Laboratories's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $522.8 million |
|---|---|
| Operating margin TTM | 12.35% |
| Gross profit TTM | $96.1 million |
| Return on assets TTM | 5.89% |
| Return on equity TTM | 11.16% |
| Profit margin | 5.01% |
| Book value | $5.34 |
| Market Capitalization | $936.7 million |
TTM: trailing 12 months
Dividend payout ratio: 4.71% of net profits
Recently Core Laboratories has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Core Laboratories shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Core Laboratories's case, that would currently equate to about $0.04 per share.
While Core Laboratories's payout ratio might seem low, this can signify that Core Laboratories is investing more in its future growth.
Core Laboratories's most recent dividend payout was on 24 November 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 November 2024 (the "ex-dividend date").
Core Laboratories's shares were split on a 2:1 basis on 8 July 2010 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Core Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Core Laboratories shares which in turn could have impacted Core Laboratories's share price.
Over the last 12 months, Core Laboratories's shares have ranged in value from as little as $13.7975 up to $25.105. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Core Laboratories's is 2.362. This would suggest that Core Laboratories's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.